Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IZXUA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Trastuzumab-Qtag2-Alexa 488-cadaverine
|
|||||
| Synonyms |
Trastuzumab-Qtag2-Alexa 488-cadaverine
Click to Show/Hide
|
|||||
| Organization |
Covalab; Centre Léon Bérard; IONTAS Ltd; Institut Curie; PSL Research University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Trastuzumab-Qtag2
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Alexa 488-cadaverine
|
Payload Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation using new Q-tag substrate of bacterial transglutaminase
|
|||||
| Elimination |
About 24% of the total MMAE ingested as part of the ADC during an ADCETRIS infusion (1.8 mg/kg) was recovered in both urine and feces over a 7-day time frame. Of the recovered MMAE, approximately 72% was found in the feces and the majority of the excreted MMAE was excreted as unchanged drug. The liver is the primary route of clearance for MMAE.
|
|||||